IRVINE, Calif., Jan. 26, 2006 (PRIMEZONE) -- "Biotech investors are funny birds. They must place their money on the slim possibility of a major discovery of the life-changing variety, while at the same time coming to grips with the reality that such discoveries rarely occur," said SmallCapSentinel analyst, D.R. Clark. "Of course, those very elements provide the impetus for this thrill ride of a sector."
"So it's no surprise that companies within this burgeoning segment are racing to broaden their portfolios and expand their product offerings," added Clark. "Late last year, Pfizer (NYSE:PFE) announced plans to buy Vicuron in order to bolster its portfolio of anti-infective products. This came on the heels of collaboration between the two companies through which some extremely significant advances in the discovery of new classes of antibiotics have emerged."
"Callisto Pharmaceuticals (AMEX:KAL), a biopharmaceutical company focused on the development of anti-cancer drugs to treat blood cancers and related diseases, announced yesterday that it had licensed a new class of cancer drugs called Degrasyns for development as anti-cancer agents," said Clark. "This is a significant departure for Callisto, transforming it from a blood-based cancer treatment company to the much larger field of solid tumors."
The informational report "The Silver Tsunami: Baby Boomers & Biotech Breakthroughs" is available at www.SmallCapSentinel.com and will address a variety of biotech and pharmaceutical-related issues for companies such as those mentioned above, as well as Celgene (Nasdaq:CELG) and Arena Pharmaceuticals (Nasdaq:ARNA).
A detailed informational report regarding Callisto Pharmaceuticals is available free to the public at the following link: http://www.trilogy-capital.com/kal_summary.aspx
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that affect results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to its accuracy or completeness. This report is neither a solicitation to buy, nor offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid fifteen hundred dollars by Callisto for preparation and distribution of this report and other advertising services. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.